Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 6/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | CDK7 | P50613 | 3/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715424 | 1.00 | LRRK2 (0.44) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL3715425 | 1.00 | LRRK2 (0.44) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL12848345 | 0.90 | LRRK2 (0.46) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL6523239 | 0.86 | LRRK2 (0.46) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL6523233 | 0.86 | LRRK2 (0.46) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL6523237 | 0.86 | LRRK2 (0.46) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL3716487 | 0.83 | TLK2 (0.48) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL3716493 | 0.83 | TLK2 (0.48) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL6531026 | 0.83 | TLK2 (0.48) | LRRK2RETTLK2PDPK1NTRK1 | |
| SCHEMBL14950690 | 0.83 | TLK2 (0.48) | LRRK2RETTLK2PDPK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9402828-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2016-08-02 | — | — | US | disclosed |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2015-07-02 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | LRRK2 521/4885RET 535/4885TLK2 457/4885 |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | LRRK2 254/4885RET 234/4885TLK2 202/4885 |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | LRRK2 324/4885RET 374/4885TLK2 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.